Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

The AHA’s PREVENT equations, compared with pooled cohort equations, can better predict 10-year ASCVD risk among US adults.